These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23601167)

  • 1. PARP inhibitors: polypharmacology versus selective inhibition.
    Ekblad T; Camaioni E; Schüler H; Macchiarulo A
    FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tankyrases as drug targets.
    Lehtiö L; Chi NW; Krauss S
    FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
    Wang B; Qian H; Yiu SM; Sun J; Zhu G
    Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemopotentiation by PARP inhibitors in cancer therapy.
    Tentori L; Graziani G
    Pharmacol Res; 2005 Jul; 52(1):25-33. PubMed ID: 15911331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
    Hottiger MO
    Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
    Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
    J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role of intracellular mono-ADP-ribosylation in cancer biology.
    Scarpa ES; Fabrizio G; Di Girolamo M
    FEBS J; 2013 Aug; 280(15):3551-62. PubMed ID: 23590234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
    Cao R
    J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From polypharmacology to target specificity: the case of PARP inhibitors.
    Liscio P; Camaioni E; Carotti A; Pellicciari R; Macchiarulo A
    Curr Top Med Chem; 2013; 13(23):2939-54. PubMed ID: 24171773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinase polypharmacology landscape of clinical PARP inhibitors.
    Antolin AA; Ameratunga M; Banerji U; Clarke PA; Workman P; Al-Lazikani B
    Sci Rep; 2020 Feb; 10(1):2585. PubMed ID: 32066817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
    Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
    Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
    Passeri D; Camaioni E; Liscio P; Sabbatini P; Ferri M; Carotti A; Giacchè N; Pellicciari R; Gioiello A; Macchiarulo A
    ChemMedChem; 2016 Jun; 11(12):1219-26. PubMed ID: 26424664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
    Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
    Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
    He JX; Yang CH; Miao ZH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.